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dynamic interactions with their bacterial and human hosts that ultimately affect human health. The current
growing interest in human resident phages is paralleled by new uses of phages, including the design of
engineered phages for therapeutic applications. Despite the increasing number of clinical trials being conducted,
the understanding of the interaction of phages and mammalian cells and tissues is still largely unknown. The
presence of phages in compartments within the body previously considered purely sterile, suggests that phages
possess a unique capability of bypassing anatomical and physiological barriers characterized by varying degrees
of selectivity and permeability. This reviewwill discuss the direct evidence of the accumulation of bacteriophages
in various tissues, focusing on the unique capability of phages to traverse relatively impermeable barriers in
mammals and its relevance to its current applications in therapy.
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Numbering over 1031 units [1], viruses are the most abundant enti-
ties in our biosphere and contribute the largest reservoir of genetic ma-
terial. Bacteriophages (phages) are the natural predators of bacteria and
are prevalent across the globe, includingwithin the humanmicrobiome,
where at least 1012 viral particles have been found per gram feces in
humans [2–5]. In addition to their lytic life cycle where phage infect,
replicate, and lyse host bacterial cells, temperate phages may also har-
bor their genomewithin the host genome as stable prophages, replicat-
ing passively [6]. Ongoing investigations of the human virome have
characterized distinct viral communities that are deeply intertwined
with their microbial host cells and human cells.
Interest in the application of phage as safe and efficient therapeutic
tools continues to grow due to (i) their lack of tropism for mammalian
cells, and (ii) an innate capability to penetrate and traverse tissues
and barriers. The restriction to infection and propagation in prokaryotic
hosts renders human hosts safe from unintentional phage infection, al-
though immunomodulatory phage-mammalian interactions should still
be considered. There is a need for prevention of genetic transfer be-
tween administered phage and host resident bacteria via transduction,
or lysogenic conversion. Undesired or uncontrolled gene transfer
could confer virulence or antibacterial resistance among bacterial popu-
lations. It has therefore been suggested to use therapeutic phages with-
out transducing potential and to profile the genomes of the phages prior
to their application in phage therapies [7].
Phage translocation throughout the body occurs rapidly upon ad-
ministration [8], and while the route of administration and initial
phage titer can greatly influence the pattern of phage distribution
[8–10], phage virion particles demonstrate an astonishingly rapid ability
to penetrate the vascular endothelium as well as other mammalian tis-
sue barriers. Phage display technology has further expanded the poten-
tial therapeutic capacity of phage; conjugation of targeting peptides or
antibodies to phage capsid proteins can extend tropism against previ-
ously untargeted bacteria, or to specifically bind eukaryotic cells. Such
targeting could facilitate sufficient therapeutic titers at the site of dis-
ease with low systemic circulation of phage [11]. In this review, we dis-
cuss the capacity of phage to penetrate and interact with human tissues
and the resulting applications.2. Phages in the circulatory system
Phages were first isolated in feces in the 20th century [12] and have
since been detected in many biomes of the human body including: the
skin [13], oral cavities [14], urine [15], respiratory tracts [16], and the di-
gestive tract [17]. Although themechanismbehind the effect has not yet
been clearly elucidated, phages are able to rapidly bypass multiple en-
dothelial, mucosal, and/or epithelial cell barriers to achieve systemic
distribution [18,19].
While phages are inherently absent in the blood of healthy humans
[15], they can been detected in the blood quickly following intravenous
administration. Dissemination to other tissues appears to be fairly rapid,
with nearly complete recovery of administered phage in the liver,
spleen, kidneys, and lungs following just a few minutes of circulation
[20,21]. Plasma half-life is dependent on the type of phage and the spe-
cific biochemistry of the capsid, but has been observed to range from
60 min (phage T7) to 6 h (phage λ) [22]. The appearance of phages in
the blood despite varied routes of administration can be attributed to
their ability to translocate across endothelial cell barriers. In a studybyWeber-Dabrowska et al., orally administered phages against Staphy-
lococcus, Escherichia, Pseudomonas and Proteus could be detected in the
blood samples of most patients with septicaemia and urinary tract in-
fections [23]. In another study, fluorescently labeled M13 particles
were able to accumulate at sites of bacterial infection within 24 h of
retro-orbital injection inmice [33]. Patients with AIDS or cardiovascular
diseases have been characterized with a higher percentage of phage
DNA compared to normal adult plasma [34,35]. Additionally, the associ-
ated bacterial host DNA is often co-detected, which may suggest the
translocation of bacteria harboring intracellular phage particles or ly-
sogenized prophages into the bloodstream, as opposed to the indepen-
dent translocation of phage particles (see Table 1).2.1. Passage across the endothelial barrier
Phages that have entered the circulatory systemwill require infiltra-
tion of the endothelium to reach the organ of interest and impart its
therapeutic effects. The endothelium forms a semi-permeable barrier
between blood and tissue where endothelial cells are typically orga-
nized in thin layers joined by tight junctions and thus separate blood
from tissue interstitial space. Arteries and veins may be surrounded by
multiple thick layers of endothelial cells, smooth muscle, and connec-
tive tissue; in contrast, capillaries are typically comprised of a single
monolayer of endothelial cells as they are the sites ofmaterial exchange.
Under homoeostatic conditions, only small molecules (less than
70 kDa) extravasate spontaneously across the endothelial barrier into
interstitial space [36]; under inflammatory conditions, larger molecules
up to 2000 kDa could extravasate spontaneously. Inflammatory condi-
tions may contribute to the increased permeability of the endothelial
barriers, as a higher abundance of phages or their DNA have been de-
tected in the blood of diseased patients [9]. The dissolution of cell junc-
tions has been observed in response to inflammatory cytokines, which
may contribute to increased paracellular movement and may explain
heightened phage accumulation in patients fighting bacterial infections
[37].
Molecular weight alone, however, does not fully account for pene-
tration of molecules across the endothelial barrier. Filament or cylindri-
cal nanoparticles demonstrate greater and prolonged penetration in
comparison with spherical counterparts [38,39]. For example, filamen-
tous phage fd measures 14,600 kDa [40] but quickly permeates across
the endothelium barrier in many vertebrates [8]. The long rod-shaped
structure most likely enhances phage penetration across the endothe-
lium. During this process however, extracellular matrix molecules in-
cluding fibronectin, gelatin, heparin may bind to phage capsids,
impeding their infiltration to target sites [41].
It has also long been recognized that endothelial cellsmaking up this
barrier are highly heterogeneous in structure [37,42]. In particular, the
presence of fenestrae furthermodulates exchange of materials between
the vasculature and the tissue. Fenestral pores (62-68 nm in diameter)
enable transport in the fenestrated endothelium surrounding the kid-
neys, digestive tract, and endocrine glands [42]. Larger fenestrate of up
to 200 nm in diameter occur in the discontinuous endothelium, which
lines the liver and bone marrow. Although there is a wide range in
size and shape across all phage families [43], many phages investigated
for use in humans could pass through fenestrae, enabling their rapid ac-
cumulation within highly vascularized organs. The ability of phage to
passage through the endothelium barrier remains of great interest as
it enables penetration into even very inaccessible areas of the body,
such as the brain.
Table 1
Tissues and barriers penetrated by phages and their sites of recovery/detection.
Infiltrated
tissue/barrier
Route of administration and site of detection Organism Phage type References
Gastrointestinal
barrier
Oral, detected in the blood Mice T4 phage (Majewska et al. 2015)
Gastrointestinal
barrier
Oral, detected in blood and urine Humans Phages against Staphylococcus, Pseudomonas,
Klebsiella, and Escherichia coli
Weber-Dabrowska, Dabrowski,







Topical and oral, cleared dermal infections Humans Phages against Psuedomonas, Staphylococcus,
Klebsiella, Proteus and Escherichia




Oral, detected in blood (with the inactivation of
gastric juice)
Rats Phages against Staphylococcus – A5/80 Międzybrodzki et al. 2017 [26]
Blood-brain
barrier –
Intranasal, detected in olfactory bulb and
hippocampus region
Mice Filamentous phage Frenkel and Solomon 2002 [27]
Blood-brain
barrier –
Intraperitoneal, detected in the brain Mice Shigella dysenteriae phage Dubos, Straus, and Pierce 1943
[28]
Dermal tissue Topical Mice Phages against Klebsiella, Kpn5 Kumari, Harjai, and Chhibber
2011 [29]
Dermal tissue Topical Guinea pigs Phages against Pseudomonas, BS24 Soothill 1994 [30]
Dermal tissue Topical Rodent and
porcine
Staphylococcus, Pseudomonas and Acinetobacter
phage cocktails
Mendes et al. 2013 [31]
Lung tissue Intranasal application, reached the lung Mice Phages against Pseudomonas, P1 Debarbieux et al. 2010 [32]
Gastrointestinal
barrier
Intraperitoneal, recovered in the lung, kidney, brain,
intestines, blood, spleen and liver







Oral, recovered in urine samples and the blood. Mice Phages against Bacillus megatherium Keller & Engley, 1958 [21]
Renal filter
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Following extravasation of phage particles across the endothelium,
phages can accumulate in other organs, such as the liver and spleen
[8,21]. Epithelial cells line the cavities and surfaces of all tissues in the
body and serve as a barrier connected by tight junctions. Transport of
material occurs primarily through transcellular pathways [44]. In
order to transcytose, a particle must first be internalized, then
transported through the intracellular trafficking network, and finally re-
leased through exocytosis [45]. In general, the epithelium transports
materials across through caveolae-mediated endocytosis (CavME)
transcytotic pathways, but other pathways are always possible.
Numerous studies have investigated the transcytosis of engineered
M13 phages employing phage display library screening, and their up-
take via receptor-mediated endocytosis. Non-specific endocytosis has
also been suggested to occur as phages or their DNA are often detected
in the bloodstream of healthy humans; however, this mechanism is still
unclear [46–48]. Nguyen et al. recently described a generalized mecha-
nism by which phages could transcytose in an apical-to-basal direction
[49]. Transcytosis of diverse phage types, including T3, T5, T7, SP01,
SPP1, and P22 phages in intact epithelial and endothelial cell layers
were investigated in vitro. 0.1% of total phages applied to the apical
side of epithelial cells were observed to transcytose, as opposed to
0.0008% traversing from the basal side. Phage particles were found in
endosomal compartments and associated with the Golgi apparatus, im-
plicating this organelle in the transcytosis mechanism [50].
2.2.1. Cellular internalization of phages
Cellular internalization can occur throughmultiple pathways, which
vary depending on the ligand and the internalizing cell type: phagocy-
tosis, macropinocytosis, clathrin-mediated endocytosis (CME) or other
energy-independent endocytic mechanisms [51]. Tian et al. (2015)
followed the uptake of fluorescent M13 in both epithelial (MCF-7 andHeLa) and endothelial (HDMEC) cell lines that were subjected to
endocytic pharmacological inhibitors [52]. M13 phage particles were
found to internalize primarily through CME and macropinocytosis in
epithelial cells, but internalized primarily through caveolae in the endo-
thelial cells.
Phages are readily internalized through receptor-mediated endocy-
tosis if conjugated with a corresponding internalizing ligand [53–59].
One study similarly tracked the internalization of M13 that displayed
cell-penetrating peptides (CPPs) 3D8 VL transbody or TAT in HeLa
cells [60]. Each CPP interacted with distinct surface receptors to initiate
endocytosis. Evidently, uptake also proceeded through different
endocytic pathways: TAT-decorated M13 was primarily through CME
while 3D8 VL-decorated M13 was primarily through CavME. After en-
docytosis, internalized phage particles localized into endosomal com-
partments, the endoplasmic reticulum, the Golgi apparatus within 6 h.
Thismay again point to a Golgi-mediated route of transcytosis although
the majority of phages were eventually routed to the lysosome for
degradation.
A growing body of evidence does suggest that phages are actually in-
herently capable of binding specific cell-surface receptors, enabling in-
ternalization by endocytic vesicles without the engineered display of
targeting ligands [61]. Recently, specific binding and uptake of
Escherichia coli phage PK1A2 into eukaryotic neuroblastoma cells were
observed in vitro [62]. This was mediated through adherence to
polysialic acid, a nine-carbon monosaccharide bearing structural simi-
larity to capsular polysaccharides present on many bacterial host - a
common route of entry for eukaryotic viruses [63]. The internalized
phages were directed to the endosomal route and localized in lyso-
somes, remaining infective for up to 24 h without impacting cell viabil-
ity. The authors raised the possibility of other eukaryotic cell surface
epitopes for phages that bear structural similarity to polysaccharides
present on bacterial hosts, which certainly warrants further investiga-
tion [62].β3 integrins present on cell surfaces are another set of possible
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specific interaction with the KGD (Lys-Gly-Asp) motif on the T4 phage
capsid [64,65].
Finally, the presence of homologs in phages and eukaryotic cells has
been suggested as indirect evidence of phage internalization into eu-
karyotic cells. Homologs of the major capsid protein gene for Chla-
mydia-infecting phages and of aerolysin-like genes have been found in
the genome of eukaryotes [66]. Conversely, eukaryotic-like domains
have been uncovered in bacteriophage genomes, which may be indica-
tive of bi-directional lateral gene transfers [67]. This could be particu-
larly worrisome for future therapeutic phage applications as
unintended horizontal gene transfers can have significantly detrimental
consequences and must be avoided as much as possible.
2.3. Immune responses in the blood
In the bloodstream, phage particles rapidly activate the immune sys-
tem and modulate its activity, although the specifics of these interac-
tions are still unclear. Multiple studies agree that clearance of phages
by nonspecific defences poses amajor problem inmaintaining sufficient
phage titers for therapeutic activity [7,68].
2.3.1. Phage clearance
The reticuloendothelial system (RES) of the spleen and liver is the
primary immune compartment responsible for the clearance of phage,
reducing phage concentrations below clinically useful levels. Kupffer
cells, which are mononuclear phagocytes from the liver, have been
shown to phagocytose T4 phages following intravenous administra-
tion [69]. Newer reports have shown that B cells are also implicated
in phage clearance, although this may be mostly phage-specific [68].
It is also hypothesized that phages have prolonged circulation in im-
munodeficient or immunosuppressed individuals due to lack of clear-
ance by immune pathways [70,71]. T7 phage circulation was
prolonged in B cell-deficient mice, although mice characterized by
other types of immunodeficiency exhibited comparable levels of
phage clearance to wild-type mice [68]. Rituximab, an antibody
against the B cell CD20 antigen, was implicated in the inhibition of
the antibody response against phage φX174 [70], a phage commonly
used in the assessment of the humoral response. Modifications to
the phage capsid could improve phage half-life, as phages with muta-
tions in their capsid proteins were capable of evading RES, prolonging
circulation and thereby prolonging their downstream therapeutic ef-
fects [72–74].
Despite the challenges of bioavailability presented by the phage-
host defence interactions, phages have achieved success in eradicating
various blood-related pathogenesis. 85% of 94 sepsis patients with ei-
ther one or mixed infections of Pseudomonas aeruginosa, Escherichia.
coli and/or Klebsiella pneumoniae who were not responsive to antibi-
otic therapy achieved complete recovery after oral administration of
phage therapy three times daily [75]. These patients experienced sig-
nificant reduction in temperature, leukocytosis, and sedimentation
rates.
Constant exposure to phages in the environment has resulted in the
presence of anti-phage antibodies in human blood. Anti-T4 antibodies
have been detected in 81% of healthy humans never subjected to
phage therapy, likely a result of natural contact with phages and from
infections by their relevant bacterial hosts [76]. Application of large
phage titers will induce the production of neutralizing antibodies
against the phages, which will undoubtedly deactivate and reduce
their therapeutic efficacy [77]. Different routes of administration appear
to generate different outcomes in antiphage antibody production. One
study showed that oral Staphylococcal phage preparations resulted in
significantly lower levels of antiphage antibodies in sera compared to
local administration [78]. This many not pose a great problem, as
Sulakvelidze et al. (2001) argued that neutralizing antibodies should
not significantly impede phage activities, as phage kinetics are muchfaster than the hosts’ production of antibodies [7,79]. In any case, re-
duced rate of neutralization can be achieved by increasing the frequency
of administration or by selecting for phages possessing different anti-
genic profiles while maintaining their host range [79]. While the loss
of phage activity is not a safety concern, the repercussions of phage-
antibody complexes should be carefully assessed, as their deposition
in the renal glomerulus can cause acute and chronic glomerulonephritis
in the patient [11,80]. To date, clinical trials have not shown evidence of
immunological complication in patients subjected to phages [71], and
the use of phage therapy continues to be prevalent in Eastern Europe,
particularly the Eliava Institute in Georgia [81–83].2.3.2. Phage immunomodulation
To date, there have been conflicting reports on the potential anti-
inflammatory action of administered bacteriophages. Bacterial lipo-
polysaccharide (LPS) elicits a strong inflammatory response in animals
and humans and could alter the immunomodulatory effects of phage
therapy preparations. Tetz et al. (2017) demonstrated that the oral ad-
ministration of a phage cocktail in mice resulted in an increased gut
permeability and endotoxemia [84]. This study also noted increased
serum LPS levels, but whether this originated from gut barrier disrup-
tion or the phage cocktail itself remains unclear Past reports of anti-
inflammatory responses following phage administration have attrib-
uted it to a direct phage modulation on cytokine activity; however,
most of these remarks pertain solely to studies measuring cytokine
levels in vitro [85]. Van Belleghem et al. (2017) demonstrated overall
anti-inflammatory (up-regulation of IL-1RN, SOCS3) but also some
pro-inflammatory effects (up-regulation of IL-1α, IL-1β, TNFα) after
administration of highly purified phages with and without endotoxins
[86]. Zhang et al. (2018) demonstrated that phages could reduce the
levels of LPS-induced inflammatory cytokines, such as TNF-α, IL1β,
IL-6, IL-8 and IL-10 in vitro, but the sole administration of purified
phages did not induce changes in these cytokine levels [87]. Most
in vivo studies to date describing phage-induced anti-inflammatory
effects often report the simultaneous clearance of bacterial infections,
which may in fact be the driving force in relieving inflammation
[88,89].
Interestingly, purified phage T4 administration appears to exert anti-
inflammatory activity to some levels as a recent in vivo study revealed
that T4 purified phages were able to significantly slow the course of
murine collagen-induced arthritis [90]. This may be induced by the
binding of T4 gp12 to LPS, which has been previously shown to reduce
inflammatory cytokine levels, including IL-1α and IL-6, in mice [91]. In-
traperitoneal application of purified T4 phages has also been shown to
inhibit reactive oxygen species (ROS) formation by cells exposed to en-
dotoxin, which may be useful in patients with conditions such as sepsis
who are particularly sensitive to excessive ROS levels and oxidative cell
death [92]. Other reported outcomes of phage therapy include acceler-
ated turnover rate of neutrophils [88,93], increased numbers of myelo-
cytes [88], reduction of cytotoxicity and bacterial invasion [89], and
reduction of T-cell proliferation in vitro [94].
Phages overall possess inherent immunomodulatory that can also be
“weaponized” against specific cancers via display of tumour-specific
targeting ligands. Tumour-specific phages developed by Eriksson et al.
demonstrated significant tumour regression when delivered intra-
tumorally [95]. In this approach, hybrid adeno-associated virus (AAV)/
phage particles encoding TNF-α and displaying an integrin binding
motif (RGD) were targeted to tumour vasculature andwere able to suc-
cessfully reduce the tumour burden in a melanoma xenograft model
[96]. In a pre-clinical trial in dogs, these targeted vectors (RGD-A-TNF)
were found to be well-tolerated even at doses of 5 × 1012 units and
found to specifically localize within tumour vasculature [97]. Follow-
up in vivo studies and the associated immune responses and role in
human health is warranted to further the potential uses of phages in
therapy.
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The ever-growing number therapeutic applications for phages have
warranted pharmacokinetic studies of phages following various routes
of administration. Fortunately, the previously unknown realm of
phage safety and efficacy is gradually being strengthened by random-
ized, double-blind and placebo-controlled phase I/II clinical trials of
phage therapy [83,98,99]. Oral phage administration is generally
regarded as safe and often the most convenient for patients, and has
been the primary route for eradicating both local infections in the gas-
trointestinal (GI) tract and in other extraintestinal tissues
[81,83,100–105]. In addition to phage therapy, phage preparations for
biocontrol to improve food safety has been approved by the FDA as
“generally considered as safe,” and are available commercially
[106,107].
Phage applications targeting extraintestinal tissues are more chal-
lenging due to the multitude of cellular barriers that have the potential
to degrade exogenous phage particles. To target these sites via the oral
route, all phage particles that enter alongside or independent of host
bacteria must pass through the stomach into the intestines then cross
the gut mucosa prior to systemic circulation. Therefore, the gastrointes-
tinal system could be considered as the first and primary barrier against
phage tissue penetration.
3.1. Passage across the gut
3.1.1. Passage across the gut mucosal barrier
Bioavailability is significantly compromised in oral administration
relative to intravenous administration [26]. Oral administration requires
phage preparations to be able to withstand the harsh conditions of the
stomach, which is highly acidic, anaerobic, and proteolytically active
[108,109]. The combined effects of the unfavourable conditions with ac-
tive immune clearance can drastically reduce phage titers to bepharma-
cologically ineffective. Phages are most stable at neutral pH of 6-8, and
titers are generally impacted with decreasing pH; this can pose a
major problem in the stomach, where the pH is estimated to be about
1-2 unless a neutralizing agent, such as CaCO3, is applied simultaneously
[100,109]. Suggested modifications to increase stability in harsh GI-like
conditions include phage encapsulation in whey alginate [110], lipo-
somes [111], and other biopolymeric matrices [112]. Miedzybrodzki
et al. (2017) demonstrated that phage T4 and antistaphylococcal
phage A5/80 titers decreased by almost 10-fold at pH 5 over the course
of an hour, but pre-treatment with Alugastrin, ranitidine, or yogurt was
able to significantly enhance phage transit from the stomach to other
sites [26]. These phages not only retained their activity, but were also
able to reach further parts of the gastrointestinal tract.
In extraintestinal applications, penetration of the gut mucosal bar-
rier is a prerequisite for effective oral delivery. The mucosa in the GI
tract consists of the epithelium, lamina propria, and the muscularis
and compartmentalizes gut bacteria to the lumen [113]. The intestinal
epithelium is a relatively impermeable physical barrier that lines the
small and large intestines and serves as a protective barrier between
the lumen and tissues to prevent direct contact between foreign parti-
cles and pathogens with the underlying epithelium [114]. It is com-
posed of a single layer of columnar epithelial cells joined by tight
junctions, containing absorptive enterocytes that constitute approxi-
mately 80% of all epithelial cells, and embedded by both M cells and
goblet cells [115]. The epithelial tissues secrete heavily glycosylated
mucin molecules, which combined with the gut commensal bacteria,
make up the “mucus”. While most mucins are secreted, 10% are
membrane-tethered [116]. Ingested phages in mice were found to be
strongly associated with the mucosa in the lumen of the large intestine
[117]. Hypervariable Ig-like capsid proteins exposed on T4 phage have
been shown to mediate the interaction with the glycans of glycopro-
teins in the mucosa, resulting in a high concentration of phages in the
mucus layer [118]. The ability of phages to adhere and pass themucosalbarrier may be dependent on the specific protein sequences on the cap-
sid [9,119].
The integrity of themucosal barrier is also substantiated by the flora
in the lumen, as inoculation of commensal bacteria in germ-free mice
have shown to improve host nutrient absorption and processing [120].
The gut microbiota is therefore thought to play an important role in
restricting the passage of exogenous phages and can control the perme-
ability of the intestinal barrier. A previous study has shown that coloni-
zation of germ-free mice with commensal bacteria can also lead to
hyperplasia of the epithelial and goblet cells that can increase the over-
all surface area of the intestinal barrier [121]. Following interactions
with the mucosal barrier, majority of the adherent phages will be de-
graded or excreted from the body [10].
There are few studies that have evidenced detection of phages in the
blood after oral administration, including Staphylococcal phage A5/80
[23,24,26]. Themechanism of this passage remains unclear and appears
to be both phage- and host species-specific [26,122]. Phages A5/80 and
T4 are similar in size and morphology, but despite the initial 1000-fold
higher dosage of T4 administered to mice, only trace amounts were de-
tected in blood compared to A5/80 [26]. Additionally, rats were not sus-
ceptible to passage of phages through the intestinal barrier, with neither
phages recovered in the bloodstream, whereas a contrasting result was
observed inmice. A proposed explanation for this phenomenonwas the
possible adsorption of phages to dead bacteria leading to irreversible
phage inactivation, and the inherent difference in microbial composi-
tion between the two species,ultimately resulting in different interac-
tions and outcomes for the two phage types [26,123].
Passage of foreign molecules into the bloodstream can be
paracellular, transcellular or mediated by M-cells. Tight junctions in
the apical side of the epithelial cells restrict the paracellular flux of for-
eign particles, restricting the size to less than 10 nm [124]. Most phage
particles are too large to penetrate through the gut epithelium through
this method. While epithelial cells carefully control the passage of sub-
stances between the lumen and the blood epithelial cells in healthy in-
dividuals, damaged guts have been described as “leaky”, whereby
phagesmay paracellularly pass through the spaces between the epithe-
lial cells, a process known as translocation [21,125–127]. This can result
in the presence of bacteria and phages in blood [126]. Transcellular
transportation is an alternative pathway for the passage of bacteria
and associated phage from the intestinal mucosa into systemic circula-
tion; however, this method requires specific receptors for transport,
and is an unlikely method of phage transit. It is possible that phages
are able to cross the barrier via the M cell-mediated pathway
[128–131]. M cells are specialized epithelial cells that act as the antigen
sampling system and possess a high capacity for transcytosis of micro-
organisms for the induction of immune responses [132,133]. M-cell-
mediated entry from the intestinal lumen to lymphoid tissues of HIV
[134], influenza virus [135], polio virus [136] and reovirus [137] have
been described. However, this method of transcytosis is likely to occur
less frequently due to the low (b1%) proportion of M cells in the epithe-
lium, and because the overall number of transported phage can be lim-
ited by the possible uptake by the macrophages or dendritic cells
[26,44].
3.1.2. Passive transport down the gut lumen
Although passage across the intestinal barrier is indeed possible,
most evidence suggests that oral application of phage leads to passive
transport through the gut and subsequent recovery in the feces. Overall,
penetration into the bloodstream is not clearly defined; there exist ex-
amples that show recovery of phages in the blood [21,23], as well as
studies that do not [72,81,83,117,138], which make it difficult to com-
pile these results into a final discernment.
In a study by Bruttin and Brussow (2005), phage was recovered in
the feces of all fifteen healthy human volunteers receiving 105 PFU/ml
of T4, one day following administration [139]. Interestingly, the admin-
isteredphage countwas very close to the fecal phage count and the fecal
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phage did not replicatewithin the commensal E. coli population. The ab-
sence of any anti-T4 immune response in this study suggested that the
phages did not enter the bloodstream, which is in agreement with an-
other study involving 120 patients with ETEC or EPEC bacterial infec-
tions [81]. This particular study also reported correlating fecal titers to
the applied phage dosage, further supporting the theory of passive tran-
sit of orally applied phages. It appears that the presence of phage-
susceptible bacteria does not directly enable self-propagation of phages
in situ [140]. It has been hypothesized that in vivo phage replication re-
quires the target bacterial population to be metabolically-competent to
permit phage replication, regardless of their high susceptibility to phage
infection in vitro. A large majority of bacterial species in the gut are in-
active due to nutritional deprivation and/or do not meet the minimum
bacterial density to support phage replication [141]. The minimum
threshold of E. coli density to support the replication of T4 phages is
about 104 CFU/ml in laboratory conditions, but this will be higher
in vivo due to a heterogenous microbial environment [10,142]. There-
fore, the lack of interactions with the intestinal mucosa may be one of
the explanations for the low/absence of phage titers in the bloodstream
following oral administration, resulting in direct transit through the in-
testinal lumen to be recovered in the feces.
A high repeated dosage can, however, permit the translocation of
phages to circulation followed by an increase in antiphage antibodies
[24]. Majewska et al. (2015) reported that 240 days of daily treatment
with high doses (approximately 2 × 1010 PFU/mouse) of phage T4 in
mice resulted in relatively high phage recovery (103 PFU/ml) in the
blood, whereas a lower dosage of 109 PFU/mouse did not [24].
3.2. Immune responses in the gut
The gut is home to one of the largest lymphoid tissues in the body,
collectively known as the gut-associated lymphoid tissue (GALT).
Phage interactions with immune cells in the gut may limit the viability
of the applied phages and consequently the bioavailability of phages.
Epithelial cells have constitutive expression of CD41a and CD61, which
may be relevant to phage T4 binding [9]. IgA is one of the hallmarks of
the humoral immune system, produced by plasma cells in the lamina
propria. The epithelial cells also possess TLRs and NOD-like receptors
that can recognize pathogen associated molecular patterns (PAMPs).
Upon recognition of foreign molecules by epithelial cells, cytokines,
such as IL-6 and TGF-β can enhance IgA secretion and suppress IgM se-
cretion by B cells, which are in close proximity to intestinal epithelial
cells in the lamina propria [143]. Intestinal barrier disruption by foreign
particles can elicit immune responses such as IgA production,which can
upregulate T and B cell production. Oral phage application has only
shown weak immune responses in several studies, suggesting that the
slight increase of antiphage antibodies does not actually impede the
outcome of phage therapy, unless administered in high doses for a
long period of time [78,83,144]. One study investigating the production
of antiphage antibodies in 122 patients showed that phage inactivation
was very low in patients treated with phages orally [145]. However,
long-term oral administration of a Staphylococcal phage cocktail in-
duced high production of IgG and IgM [144]. Similarly, Majewska et al.
(2015) demonstrated that when a high oral dosage of phage T4was ad-
ministered over a long period of time, IgG and IgAwere induced after 36
and 79 days, respectively, with increased IgA levels hindering the gut
transit of T4 [24]. Antiphage antibody response appears to be phage
type-dependent, as phages will harbour different surface proteins con-
ferring various levels of immunogenicity [24].
The resident gut phage community in the gut play a specific role in
health and disease, even providing defence to the human host frombac-
terial pathogens. Barr et al. (2015) describe amodelwhereby the adher-
ence of phage to the mucosa (BAM model) to confer immunity and
antimicrobial defense to the underlying human epithelium from patho-
gens [80]. It has later been proposed that mucus-adherent phagesexhibit a reduced diffusive motion that may increase the chance of en-
countering a bacterial host before it leaves the mucus. This subdiffusive
motionmay be beneficial in the gut environmentwhere there are lower
bacterial concentrations and enable a more “thorough” search of the
local area for the host [146]. The aforementioned coliphages such as
T4, that appear to exert immunosuppression, may also play a role in
downregulating gut immune cells and prevent inflammation [147].
Phages can also contribute in our defences against invaders not only
by lysis of pathogens, but by remaining integrated in the commensal
bacteria as prophages and conferring immunity to the host from related
phage types, as well as through horizontal gene transfer of beneficial
genes between the bacterial hosts [148,149]. The balance between
lysis and lysogeny of phages must be maintained for the healthy gut
and the disruption of the gut phage population has been correlated to
disease [6,17,150,151]
4. Phages in the brain
The blood brain barrier (BBB) is a group of endothelial cells that
present perhaps the greatest endothelial barrier in general drug deliv-
ery. Typically, molecules capable of passing through this barrier have
at least one of the following characteristics: they are less than 500 Da;
they are very lipophilic; or they are structurally similar to compounds
that enter the brain through active transport [152,153]. This tightly reg-
ulated system poses a serious obstacle in drug delivery to the central
nervous system (CNS), and prevents reliable treatment for many CNS
disorders [152]. Phages have long been recognized for their ability accu-
mulate in the brain, bypassing this barrier with apparent ease [8,10].
Their use as CNS drugdelivery vehicles is therefore of particular interest.
4.1. Passage across the blood brain barrier
Overcoming the BBB hurdle has been attempted inmanyways, with
many novel approaches utilizing phages [28,152,154]. Evidence of
phage transport across the BBB was first described in 1943 by Dubos
et al. [28]. They noticed that when phages were injected intraperitone-
ally into mice, phage populations could be isolated from the brain as
early as 1 h after administration. Asmight be expected, phages persisted
for longer periods of time and in higher concentrations in the presence
of their bacterial host (Shigella dysenteriae in this study).
Frenkel and Solomon first reported the surprising ability of filamen-
tous phageM13 to penetrate the brain in 2002 [27]. Despite its large size
(900 nm in length), the phage could accumulate in the brain shortly
after nasal administration.Wildtype M13were detectable in the hippo-
campus and olfactory bulb of BALB/C mice after intranasal administra-
tion of 1011 phage particles. Frenkel and Solomon attributed the
ability to penetrate the BBB to the linear structure of the phage, a con-
clusion that has since held as phage M13 most likely penetrates the en-
dothelium elsewhere by the same mechanism. They observed that
spheroid phages were unable to exhibit the same level of penetration.
Ksendzovsky et al. (2012) more recently improved transport of M13
to the brain by using convection-enhanced delivery (CED), which had
previously showed success in improving brain transport with much
smaller viruses and nanoparticles [155].While phage titers were not re-
ported, phageM13were found to successfully distribute across grey and
white matter including frontal white matter, suggesting that active ax-
onal transport mechanisms such as axonal transcytosis may play a
role in moving phage within the brain.
Phage display of BBB-penetrating peptides can further increase ac-
cumulation and prolong phage half-life in the brain, resulting in more
effective concentrations [11]. Conjugation of an N-terminal transferrin
motif (CRTISGPSVC) to the capsid of an M13 phage derivative enabled
receptor-mediated transcytosis through the BBB, thereby improving
phage penetration by a factor of 100 [156,157]. Infiltration was greater
in orthotopic mouse models of glioblastoma, which is characterized by
increased expression of transferrin receptors [157]. Biopanning [158]
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Urich et al. used phage T7 for in vivo functional screening of cerebrospi-
nal fluid (CSF) homing peptides, observing that while wildtype phage
T7 half-life had a half-life of approximately 25 min in CSF, four rounds
of panning yielded decorated phage that could persist in CSF for over
40 h.4.2. Therapeutic use of phages in the brain
In addition to its BBB-penetrating capacity, phage M13 has further-
more demonstrated intrinsic characteristics that are ideal in the treat-
ment of neurodegenerative diseases, including Parkinson’s disease
(PD) and Alzheimer’s disease (AD). Dimant et al. (2009, 2010) observed
the inhibitory effects of phage M13 on α-synuclein aggregation, a hall-
mark of PD, in an SH-SY5Y cell line model [160,161]. Although the
mechanisms behind these disaggregation effectswere not deeply inves-
tigated, the authors postulated preferential interactions between the fi-
brils and the phage. In a separate study,M13was shown to remodel and
repair amyloid β plaques through a general amyloid interaction motif
(GAIM) present on its pIII capsid protein [162]. This holds great promise
for novel phage-based GAIM therapeutics as they can also target and
dissociate misfolded proteins in AD, PD, and prion diseases [163].
The inherent natural specificity of phages toward their bacterial prey
enables their employment as detectors of bacterial infection in the CNS,
such as for Tuberclulous meningitis [164–171]. Bacterial detection can
mediated through the use of reporter phages carrying the firefly lucifer-
ase gene (luc) [164,167–174]. This technique has also been used to de-
tect Listeria monocytogenes, Yersinia pestis, Bacillus anthracis and
Mycobacterium tuberculosis [164–171]. Alternatively, reporter genes in
phage could also be used for imaging cellular distribution within the
CNS in vivo, providing an inexpensive alternative to MRI and PET
scans [175].
Interestingly, phage fd was used in a proof of concept in the treat-
ment of chronic addictions [176]. Carrera et al. conjugated anticocaine
antibodies to the major coat protein of phage fd. When delivered intra-
nasally, the phage-antibody conjugates were able to pass through the
BBB and block the psychoactive effects of cocaine in a murine model.
This technique could potentially be extended to other addiction treat-
ments, such as opioid use, which has been a growing issue over the
last two decades [176,177].
This same technique can be applied to deliver other genes directly to
the CNS for the treatment of various neurological disorders, including
mood and anxiety disorders, which are among themost commonmen-
tal disorders [59,178]. Preliminary results of gene transfers utilizing her-
pes simplex virus vector have been positive in mood disorders;
however, phage-based therapies have yet to be investigated [179].
Phage-BBB interaction is still a hugely lacking research area with tre-
mendous potential in the future of neurological research both in terms
of treatment and diagnosis [28,162,176,180]. Increasing the penetrative
ability of phage is still an ongoing challenge and will be very necessary
in order to increase their own therapeutic activity and/or their thera-
peutic ferrying ability in the CNS [157,181].5. Phages on the skin
The twomajor routes of phage delivery under study are oral and in-
travenous administration. Direct delivery of phages directly to an organ
of interest – bypassing vascular and endothelial barrier obstacles –
could prevent loss of phage titer to immune and RES clearance and
could therefore yield a greater therapeutic effect. However, localized in-
jection to certain inaccessible sites is not favourable as this tends to be
invasive and damaging to the surrounding tissue [182]. In contrast, lo-
calized, non-invasive application of phage to readily accessible organs,
including the skin, holds much greater promise.5.1. Passage across the skin
Human skin serves as the first line of defence against pathogens as a
physical barrier, and it is composed of various layers.While literature on
how phage might traverse these layers is scarce, it is now very well
known that phage therapy can be highly effective against skin bacterial
infections [104]. Bacterial infections can arise from the epidermis, der-
mis, subcutaneous and adipose tissues and muscle fascia and multiply
in the regions of disruption in the integumentary barrier [183]. While
applications of phage in treating dermal wounds and infections have
been well documented in the past decade, the mechanisms behind
their ability to infiltrate past layers of dermal tissuehas not beenwell in-
vestigated. Topical applications of phages in hydrogel formulations to
treat Klebsiella infections in mice have also effectively reduced mortal-
ity, once again confirming phage ability to penetrate layers of dermis
[29]. Full-thickness burn wound infections were induced in mice, and
K. pneumoniae was applied topically to the defective site. Klebsiella
phage Kpn5 provided protection on the first day (100%) and declined
overtime, but still provided the highest level of survival by day 7
(63%), as compared to the untreated group (0%). Once released from
the hydrogel formulation, the phagewere able to penetrate the infected
area and infect the bacterial host to effectively prevent bacteraemia.
5.2. Therapeutic use of phages on the skin
Phages are ubiquitous to the surface of the skin as are their host bac-
teria, such as Propionibacterium or Staphylococcus bacteriophage. [13].
Burn wounds commonly result in bacteremia and septic shock, as op-
portunistic bacteria colonize and rapidlymultiply in the damaged tissue
rendered immunosuppressed and eventually disseminate systemically
[184,185]. Phage therapy in wound-healing applications initially
began in the former Soviet Union and has since been gaining popularity
in the last decade. In addition to burn wound experimental models,
phages have shown to effectively combat dermal bacterial infections
caused by chronic illnesses, such as diabetes mellitus. Mendes et al.
(2013) observed smaller epithelial and dermal gaps as a result of
phage therapy in S. aureus and P. aeruginosa infections [31]. Wounds
were inflicted in rats with chemically-induced diabetes mellitus, and
were inoculated with S. aureus, P. aeruginosa, or A. baumannii. 4, 5, and
8 days post-wounding. Debridement was performed, and phage cock-
tails were administered topically twice-daily. The dissemination of
phages to the sites of bacterial hosts resulted in the significant decline
of colony counts in all three test groups by day 4, in addition to the over-
all reduction in the wound surface areas caused by S. aureus and
P. aeruginosa. Again, interspecies differences played a role in the out-
come of phage therapy was apparent, as the results were not as pro-
nounced in porcine models as compared to rodents.
Phage therapy in experimental animal models holds an impressive
record, but the penetrative and other pharmacokinetic parameters in
human skin infections have not been extensively studied. Soothill
et al. (1994) demonstrated the ability of lytic phages to permeate
dead dermis to prevent skin graft destruction by P. aeruginosa [30].
Skin grafts of guinea pigs extending down to the subcutaneous fat was
excised, andwas inoculatedwith bacteria (106 CFU), followed by the re-
placement of the graft back to its initial position. Co-administration of
107 PFU phage permitted graft survival, otherwise failure of graft uptake
was observed uniformly in all the guinea pigs. Phage therapy in clearing
human wound infections is an emerging area of research in North
America. As an early example of topical applications of phage in
humans, Cislo et al. (1987) reported the use of phage therapy for faster
healing of chronic suppurative skin infections caused by Pseudomonas,
Staphylococcus, Klebsiella, Proteus and Escherichia [25]. Improvements –
ranging from suppression of local inflammation, fully negative bacterio-
logic tests, and faster healing of ulcers –were observed in 25 out of the
31 participating patients. The follow-up study published in 2000 ex-
panded on this and reported full recovery of 85.9% cases in 1307
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trial was set out in 2009 by Rhoads et al. to examine the safety profile
of S. aureus, P. aeruginosa, and E. coli-targeting phages in 42 patients
with chronic venous leg ulcers, and found no adverse events associated
with the therapy [187].
While phage therapy is widely acclaimed in Eastern Europe, there
are no phage products commercially available for human therapy in
the West, mainly due to the lack of controlled, randomized trials, with
little English translation of the existing documentation [188]. The Eliava
Institute in Georgia developed a commercially available, topical phage
application called the PhageBioDerm: a biopolymer bandage consisting
of a cocktail of lytic phages, antibiotics, and analgesic to treat burn
wound victims with a sustained release following its application
[182,189]. This particular formulation of phages is referred to as
“pyophage,” which is comprised of phages that target Staphylococcus,
Streptococcus, Pseudomonas, Proteus and E. coli, and is continuously up-
dated every 6 months to offset any form of resistance that may arise
[189,190]. There is a small, but growing, number of companies
established in North America that have begun controlled trials for prod-
ucts for phage therapy under various stages of development; including a
phage preparation for venous leg ulcers (Intralytix, n.d.). Currently,
there is an ongoing phase I/II clinical trial called Phagoburn – a collabo-
rative project in Europe that was initially launched in 2015 involving
220 patients that evaluates the safety and effectiveness of phage cock-
tails to target E. coli or P. aeruginosa in burn wound infections (http://
www.phagoburn.eu).
6. Phages in the respiratory system
Another relatively accessible organ for phage delivery is the lungs.
Phage delivery into the lungs can occur through multiple routes. After
oral or intravenous administration, phage can enter the lungs via the
circulatory system. Alternatively, phage may be delivered directly to
lung tissue either nasally or by injection. While there is a growing
body of evidence demonstrating successful phage accumulation in the
lungs after oral exposure via the bloodstream, presentation of sufficient
numbers of phages to respiratory epithelial tissue is probably better
achieved through nasal or tracheal delivery [8,119,191].
6.1. Passage into the lungs
Aerosol preparations of phage T-2r have been reported as early as
1956 [192,193]. Liquid aerosol preparations have long been studied,
generally against P. aeruginosa lung infectionmodels [32]. Intranasal in-
stillation of liquid phage suspensions greatly improved survival in mice
infected with P. aeruginosa [32]. Phage lysis of bacteria began as early as
6 h after intranasal administration [32]. The same group later reported
that a single dose intranasal treatment of phage could fully treat or pre-
vent P. aeruginosa infection in mice [194]. However, controlled intrana-
sal instillation is easier to carry out in animal models so it may not
necessarily reflect the success of aerosol drug delivery in the clinical
setting.
Nebulization of phages holds great promise, particularly as nebu-
lized antibacterials have been previously met with positive results in
cystic fibrosis patients [192,195,196]. Golshahi et al (2008) investigated
nebulization of Burkholderia cepacia complex (BCC) bacteriophage,
assessing two nebulizers (Pari LC star and eFlow) and their effect on re-
sultant active phage titers [195]. They found that the BCC phages were
able to survive nebulization and neither nebulizer substantially de-
creased the active phage titer. Another study investigated nebulization
of a phage cocktail against P. aeruginosa using a Porta-neb nebulizer
[197]. Again, no significant difference was found in the total number
of infective phages before and after the nebulization process and
delivery.
In contrast to liquid aerosols, formulation of dry inhalable powders
has great advantages for long-term stability [198], storage, andtransport [196]. Golshahi et al. (2010) reported an aerolizing dry pow-
der formulation of phages KS4-M and ΦKZ [199]. Lyophilization with
lactose and lactoferrin resulted in a titer loss around 1 log PFU/mL, but
aerosol delivery did not result in significant decrease in predicted lung
deposition of phage. Matinkhoo et al. (2011) formulated dry powders
of individual phage suspensions and phage cocktails including phages
KS4-M, KS14,ΦKZ/D3,ΦKZ/D3/KS4-M by spray drying, with excipients
trehalose and leucine [200]. Similarly, they showed a titer loss less than
1 log PFU/mL after formulation. Vandenheuvel et al. (2013) explored
formulations of dry powders across a range of phages by spray drying,
withmultiple saccharide excipients [201]. Leung et al. (2016) compared
spray freeze drying against spray drying to produce phage powders, ob-
serving a higher retention of phage particles through spray drying [196].
More recently, Chang et al. (2017) investigated seven spray dried
phages against P. aeruginosa, comparing excipients trehalose, lactose,
and leucine [202]. Excipient composition greatly influenced the degree
of titer loss [201,202] after spray drying and the resultant stability of
the phage formulation [198,203]. While direct delivery of phages to
the lungs through inhalation therapy could improve accessibility of
phages to sites of infection, onemajor limitation is the possibility of het-
erogeneous placement of the phages, rendering treatment less effective
[119,191].6.2. Therapeutic uses of phage in the lungs
Perhaps the earliest reported use of phages against in the lung may
be in a 1936 case where infection by a “colon bacillus” was treated by
directly applying a “colon lytic filtrate” to the infected area [204]. Nota-
bly in this case, the patient experienced high fever during the course of
treatment, possibly due to LPS presence in the phage preparation. Since
then, studies have reported overall high success rates in treating lung
infections with phage therapy (reviewed more thoroughly elsewhere
[191]).
The use of phages appears to be particularly effective in the treat-
ment of P. aeruginosa, an opportunistic bacteria commonly found in
the lungs of patients with cystic fibrosis [205]. It has been shown that
phages are able to serve as both treatment and prophylactic for these in-
fections with high success rates. Burkholderia cepacia, another opportu-
nistic bacteria seen in the lungs of cystic fibrosis patients, was also
effectively treated using a phage therapy approach. In addition to cystic
fibrosis, phages have been able to successfully treat Pseudomonas
fluorescens and Staphylococcus lentus respiratory infections [206].
Phage S13 has also been shown to reduce septicemia from opportu-
nistic Staphylococcus aureus infection in the lungs of patients with cystic
fibrosis [207]. Intraperitoneal treatment with S13 was shown to de-
crease lethality and increase phage count in the lungs, spleen and
other organs. Interestingly, even though the phage count increased in
the lungs, the bacterial count did not change significantly. This was
not the case in other tissues and a possible explanation may be related
to an overall poor distribution of phage in the lungs due to the adminis-
tration route (intraperitoneal, rather than nasal or tracheal).
More recently, a group investigated intranasal lytic phage therapy
against carbapenem-resistant Acinetobacter baumannii, a major causa-
tive agent in hospital-acquired infections, in mice [208]. They observed
greater therapeutic effect against A. baumannii-mediated pneumonia
when thephagewasdelivered earlier than later (1h post-bacterial chal-
lenge compared to 4 or 24 h post-challenge), underscoring the impor-
tance of early treatment. Interestingly, they found that the delivered
phage persisted at high titers even after 24 h, suggesting that most
phage clearance occurs in systemic delivery.
As is often the case, phage therapy can be highly effective in clearing
some respiratory infections while being completely ineffective for
others, illustrating a knowledge gap that requires extensive investiga-
tion before phages can be used clinically as an antibacterial treatment
in the respiratory system.
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Phages are exceptionally simple genetically and therefore, excep-
tionally easy to re-engineer for infinitely many functions. Of particular
interest here is the ability to engineer phages for targeted cellular up-
take. Phage display can theoretically enable receptor-mediated inter-
nalization into any cell depending on the conjugated peptide, while
the phage genome can be modified to carry any gene of interest
[11,209].Whilemany of these engineered phages have only been exam-
ined in vitro, they hold much promise for future therapeutic phage
applications.
Since themajority of phage applications have concentrated onmod-
ifications of the phage capsid, the genetic material is simply unneces-
sary. Phages gutted of their genome are not only non-replicative, but
can instead encode a gene of interest for transduction as gene delivery
vehicles. These phage vectors can exploit the penetrative ability of
phages for targeted gene delivery. Incorporation of eukaryotic viral
components can furthermore confer mammalian cell tropism upon
phages and has seen much success. Filamentous phage display of the
adenoviral penton basewas observed to improve cell attachment, inter-
nalization, and nuclear entry for successful gene transduction [210]. The
adenoviral penton base facilitates escape from the endosomal compart-
ment, improving intracellular release of phage [211]. Extending this fur-
ther, Hajitou et al. developed hybrid phage/viral vectors that employed
both peptide and genetic elements derived from adenoviral associated
virus (AAV) [212–213]. Display of an AAV-derived peptide sequence
stimulated endocytosis of the chimeric phage particles and greatly im-
proved internalization efficiency, although the majority of internalized
hybrid phage particles remained trapped in the endolysosomal com-
partment [214].
Phage T4 was also engineered for targeted cellular uptake. Modified
T4 particles were decorated with cell-penetrating peptides (CPP) or
targeting ligands and packaged with a luciferase expressing plasmid
for transgene delivery both in vitro and in vivo [215]. T4 heads deco-
rated with CPPs TAT or Antp were efficiently endocytosed by HEK293T
cells with efficient transgene expression. T4 particles targeted to den-
dritic cells were internalized specifically by in vitro dendritic cells and
in a murine model. Their gene delivery capacity was demonstrated
with the delivery of multiple reporter genes. Phage T4 heads simulta-
neously packaged with luciferase and GFP plasmids and decorated
with β-galactosidase molecules were able to successfully deliver all
three markers to cells in vitro. Phage T4 is a very promising targetable
high-capacity gene and protein delivery vehicle, particularly in cancer.
Phage T4 anticancer activity was observed in vivo as early as 1940.
Most notably, the KGD motif capsid protein gp24 of phage T4 has
integrin targeting capabilities. A substrain of phage T4, HAP1,was inves-
tigated for its affinity for melanoma cells [65], mediated through inter-
actions between phage capsid protein gp24 and β3 integrin.
Intraperitoneal or intravenous administration of purified T4 reduced tu-
mour burden in amelanomamousemodel in a dose-dependentmanner
[216] while non-purified lysates stimulated tumour growth, an effect
attributed to the presence of bacterial cell components. In contrast,
oral administration of both purified and non-purified HAP1 lysates
both reduced tumour burden similarly [217]. The anticancer effect
most likely arises from localized recruitment of tumour-infiltrating neu-
trophils [95], largely through tumour-localized stimulation of Toll-like
receptor (TLR) signalling [218].
Although the ability of therapeutic phages to reach the epithelial cell
layer and bypass this barrier to reach various sites throughout the body
can be highly beneficial in enhancing its therapeutic potential, this
unique penetrative capacity of phages can also be a double-edged
sword. Resident phages in the gut can alter themicrobiota, and even in-
crease the permeability of the epithelial cells – creating similar condi-
tions of guts of diseased patients, in which inflammation and immune
activation can occur. Defects in the intestinal barrier function has been
associated with celiac disease, colorectal cancer, irritable bowelsyndrome and inflammatory bowel disease [219]. It bears repeating
that much remains unknown regarding exogenous phage interaction
with the host body immune system and gut microbiota so we must re-
main cautious as we proceed.
8. Summary
Phages possess a wide range of therapeutic potential. They are:
(i) highly specific against bacterial targets, (ii) highly penetrative in var-
ious mammalian tissues, bypassing anatomical barriers that are rela-
tively impermeable, (iii) modifiable to meet the needs of the
therapeutic purpose, and (iv) safe, as demonstrated by the majority of
clinical trials. Phage display can also further increase the penetrative
ability and add other activities depending on the conjugated peptide.
It has been suggested that with the rapid advancements in synthetic bi-
ology, phages targeting against virtually any bacteria will soon be possi-
ble [11,209]. Phages also have immunomodulating properties, which
could be highly exploitable in the future although the conflicting reports
on the nature of this activity necessitates future investigation before
that can happen.
Therapeutic use of phages needs to overcome one very major hur-
dle: achieving sufficient numbers of phage for therapeutic activity. In
eradicating bacterial infections, attaining a “killing titer” is difficult if
bacteria are able to infiltrate into organs that are less accessible to
phage; there may therefore be a need to administer high or repeated
phage doses, instead of depending on phages to replicate in situ utilizing
the bacterial pathogen [190]. Fortunately, high titers of phage have not
yet shown any negative impact in healthy humans. Unfortunately, most
proof-of-principle demonstrations of phage therapeutic applications
use very high titers of phage to achieve efficacy, an unlikely situation
in practice, especially after immune clearance.
Many challenges exist in employing phage as therapeutics since
there are many variables to be considered, several of which have
come up again and again over the course of this review: routes of ad-
ministration, phage type, frequency of administration, dosage, modifi-
cations of the phage capsid, interspecies differences in the mammalian
host, and more. Phages require thorough investigation of the immuno-
logical response they may elicit, as well as extensive purification steps
prior to their administration, as bacterial contaminants can be detri-
mental and elicit highly pathophysiological effects. The growing num-
ber of publications emerging in the last decade along with increasing
industry interest in phage therapy marks very encouraging progress in
repairing the knowledge gap necessary for phage therapeutic
application.
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